Trial in Progress Poster to be Presented Today at the 2019 American Society of Clinical Oncology Annual Meeting WOBURN, Mass. , June 01, 2019 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™